title: Lymphatic vessel density, microvessel density and lymphangiogenic growth factor expression in colorectal cancer.
abstract: OBJECTIVE
  Microvessel density (MVD) has been studied as a prognostic marker in human cancers. Quantification of lymphatic vessel density (LVD) is now possible by using new antibodies. Expression of the lymphangiogenic growth factors, VEGF-C and VEGF-D, is associated with poorer clinicopathological outcomes in various tumours. The aim of this study was to quantify LVD and MVD in colorectal cancer, determine the relationship between LVD, MVD and clinicopathological variables and examine the relationship between LVD and tumour expression of VEGF-C and VEGF-D.
  
  
  METHODS
  Thirty primary colorectal cancers were immunostained for CD34, lymph vessel endothelial hyaluronan receptor-1 (LYVE-1), VEGF-A and VEGF-D using standard techniques. LVD and MVD were determined by Chalkley grid counting. Tumours were assessed for the presence or absence of LYVE-1 positive lymphatics at different areas within the tumour and the tumour was scored for VEGF-C and VEGF-D immunostaining intensity at the invading tumour edge. Non-parametric tests were used for statistical analysis and a P-value of <0.05 was taken as significant.
  
  
  RESULTS
  Lymph vessel endothelial hyaluronan receptor-1 was an excellent lymphatic vessel marker. Within normal bowel wall, lymphatic vessels were found rarely in the superficial colonic mucosa, but were numerous in the submucosa and muscularis propria. In the majority of tumours, lymphatic vessels were located in the peri-tumoural area, intra-tumoural vessels were sparse and tended to be narrow with closed lumina. At the invading tumour edge, VEGF-C expression was higher (P = 0.028) and VEGF-D expression lower (P = 0.011), in tumours in which lymphatic vessels were present. No significant differences between LVD and any clinicopathological variable or route of metastasis were identified.
  
  
  CONCLUSIONS
  Lymphatic vessel density and MVD can be quantified in colorectal carcinoma using immunohistochemical techniques. The balance between expression of VEGF-C and VEGF-D at the invading tumour edge may enhance lymphatic metastasis, by promoting tumour lymphangiogenesis or by activation of pre-existing lymphatic vessels. No relationship was identified between LVD and clinicopathological variables.
authors.affiliation: Department of Surgery, Christie Hospital NHS Trust, Manchester, UK. saraheduff@aol.com
authors.forename: S E
authors.initials: SE
authors.lastname: Duff
authors.forename: M
authors.initials: M
authors.lastname: Jeziorska
authors.forename: S
authors.initials: S
authors.lastname: Kumar
authors.forename: N
authors.initials: N
authors.lastname: Haboubi
authors.forename: D
authors.initials: D
authors.lastname: Sherlock
authors.forename: S T
authors.initials: ST
authors.lastname: O'Dwyer
authors.forename: G C
authors.initials: GC
authors.lastname: Jayson
mesh_terms: D000230:Adenocarcinoma / Q000098:blood supply / Q000473:pathology* / Q000503:physiopathology; D015179:Colorectal Neoplasms / Q000098:blood supply / Q000473:pathology* / Q000503:physiopathology; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D042583:Lymphangiogenesis; D008207:Lymphatic Metastasis; D042601:Lymphatic Vessels / Q000473:pathology* / Q000502:physiology; D009389:Neovascularization, Pathologic; D042582:Vascular Endothelial Growth Factor C / Q000378:metabolism*; D042643:Vascular Endothelial Growth Factor D / Q000378:metabolism*
chemical_list: C467486:VEGFC protein, human; D042582:Vascular Endothelial Growth Factor C; D042643:Vascular Endothelial Growth Factor D